Article Abstract

Quality of life after ultra-hypofractionated radiotherapy for prostate cancer: the challenge of RTOG 0938 trial

Authors: Stefano Arcangeli, Valentina Pinzi


In the Red Journal, Lukka and colleagues reported optimal quality of life (QoL) outcomes of the NRG Oncology RTOG 0938 trial (1). This trial randomly compared two short radiation schedules of 5 and 12 fractions of 7.25 and 4.3 Gy each, respectively, for the treatment of localized, low risk prostate cancer. The primary endpoint was the proportion of patients with a change in bowel and urinary EPIC-50 score at 1-year.